Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Bisphosphonate treatment of lytic bone metastases
Allan Lipton
, James R. Berenson
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Editorial
›
peer-review
11
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bisphosphonate treatment of lytic bone metastases'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Skeletal-related Events
100%
Bisphosphonates
100%
Survival Benefit
100%
Performance Status
100%
Bone Pain
100%
Bisphosphonate Treatment
100%
Osteoclastic Activity
100%
Lytic Bone Metastasis
100%
Tumor
50%
Multiple Myeloma
50%
Bone Metastasis
50%
Quality of Life
50%
Quality Performance
50%
Placebo Groups
50%
Placebo
50%
Phase II Study
50%
Breast Cancer
50%
Chemotherapy
50%
Osteoclast
50%
Bone Resorption
50%
Cancer Clinical Trials
50%
Potent Inhibitor
50%
Patients with Breast Cancer
50%
2-phase
50%
Clodronate
50%
Osteoclast Activation
50%
Aminobisphosphonates
50%
Lytic Bone Disease
50%
Therapeutic Benefits
50%
Analgesic Use
50%
Tumor-induced Osteolysis
50%
Delayed Deterioration
50%
Medicine and Dentistry
Bone Metastasis
100%
Bisphosphonate
100%
Pamidronic Acid
100%
Neoplasm
40%
Breast Cancer
40%
Placebo
40%
Osteolysis
40%
Bone Pain
40%
Deterioration
40%
Multiple Myeloma
20%
Quality of Life
20%
Osteoclast
20%
Bone Disease
20%
Osteoclast Activity
20%
Clodronic Acid
20%
Anodyne
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bone Metastasis
100%
Bisphosphonic Acid Derivative
100%
Pamidronic Acid
100%
Breast Cancer
40%
Neoplasm
40%
Placebo
40%
Bone Pain
40%
Deterioration
40%
Multiple Myeloma
20%
Chemotherapy
20%
Bone Disease
20%
Analgesic Agent
20%
Clodronic Acid
20%
Immunology and Microbiology
Osteolysis
100%
Osteoclast Activity
50%
Multiple Myeloma
50%
Osteoclast
50%